ABSTRACT

**Introduction:** Primary malignant melanoma of the esophagus is a rare tumor representing only 0.1-0.2% of esophageal malignancies. The goal of the study was to report on the management of a new case diagnosed and treated in our site.

**Case report:** A 67-year-old patient presented with dysphagia to solids with no other remarkable history or associated skin lesions. He underwent gastroscopy, which revealed a polypoid mass suggestive of neoplasm in the distal third of the esophagus. Biopsy indicated melanoma with positive immunohistochemical markers S100 and HMB45, and negative cytokeratins and CEA. Computerized tomography (CT) and positron-emission tomography (PET) scans showed no local infiltration or distant metastases. An Ivor-Lewis esophagectomy procedure was performed with regional lymphadenectomy. Postoperative stay lasted for three weeks, and no remarkable postsurgical complications arose. The pathological study of the specimen confirmed the diagnosis of primary esophageal melanoma.

**Discussion:** Primary malignant melanoma of the esophagus has an unfortunate prognosis as it is an aggressive tumor usually diagnosed at an advanced stage, with local invasion and metastatic disease. Currently, surgery is the treatment of choice, with the remaining adjuvant therapies obtaining limited results.

**Key words:** Primary melanoma of esophagus. Metastasis. Treatment.
Surgical management included Ivor-Lewis subtotal esophagogastrectomy with regional, celiac and mediastinal lymphadenectomy, posterior mediastinal gastroplasty, and anastomosis at the azygos arch level, in addition to feeding jejunostomy.

Postoperative stay lasted for three weeks, and the patient had a favorable course with no complications, normal diet being tolerated at discharge.

Gross pathology of the surgical specimen showed a pigmented polypoid, focally ulcerated lesion with radial growth, 4.3 x 2.4 x 2 cm in size, at the distal third of the esophagus (Fig. 2). Under the microscope the lesion was made up with squamous and fusiform neoplastic cells, some of them containing melanin pigment, with marked nuclear atypia and mitotic activity (Fig. 3). Radial growth foci were identified near the polypoid lesion (Fig. 4). Tumor infiltration reached the submucosal layer. Proximal, distal and circumferential margins remained tumor-free. Of all 20 dissected nodes, only one had melanoma micrometastasis.

Tumor cells were positive for S100, Melan-A and HMB45, with immunohistochemical staining (Fig. 5). Staining was negative for cytokeratin, AE1/AE3 and CEA.
These pathological findings supported a definitive diagnosis with stage IIA (T2N0M0) primary malignant melanoma of the esophagus.

DISCUSSION

Primary malignant melanoma of the esophagus is a rare condition (1,2). Diagnosis remained uncertain until benign melanocytes were found in the esophageal mucosa in 4 of 100 autopsies by Pava et al. (3). Later, Ohashi (4) and colleagues acknowledged this observation by showing the presence of melanocytes in the esophageal mucosa of 8% of the population.

Risk factors for this disease remain unclear, although it is more common in males between the sixth and seventh decades of life. Our patient meets these requirements without further risk factors, as alcohol and smoking seem to be unrelated, and DiConstanzo found them to be negative in a series of six primary esophageal melanomas recorded through 35 years (5).

Clinical presentation is similar to that of any esophageal malignancy, with dysphagia in 73% of patients, weight loss in 72%, retrosternal pain in 44%, and upper GI bleeding in only 10% (6). Our patient presented for dysphagia to solids of two-month standing with no other associated manifestations.

Upper GI endoscopy reveals an intraluminal polypoid lesion, either non-pigmented or brownish drab in color in 85% of patients, with an occasionally ulcerated or intact mucosa. The most common site (86%) includes the middle and distal thirds of the esophagus (7). Cases with multiple lesions have been described in association with skin melanoma metastases to the esophagus, which must be differentiated from the satellite lesions developing in up to 12% of patients. Our patient had no satellite lesions on endoscopy, only a single polypoid mass.

As with other sites, esophageal melanoma is also highly aggressive because of its tendency to grow vertically within the wall, both at the mucosal and submucosal level, with invasion of both lymph and blood vessels, which results in a high rate of metastatic disease at diagnosis. The first organ to become involved is the liver, followed by the mediastinum, lung, and brain (8). In our patient neither CT nor PET/CT scans demonstrated nodal or distant metastasis at the time of diagnosis.

Management is dependent upon the presence of distant metastasis and patient status. Surgery is the treatment of choice. Specifically for some authors (9) total esophagectomy plus lymphadenectomy should be the initial option since satellite lesions are often overlooked by preoperative diagnosis. As no such lesions were identified in our case, esophagectomy to the upper third was deemed as sufficient, with lesser gastric curvature (from the angular notch) and fundus resection, and extended lymphadenectomy in the mediastinum, paracardial region, lesser gastric curvature, and celiac trunk and its three main branches. Pathology demonstrated infiltration-free margins on the specimen with no satellite lesions and a total of twenty isolated nodes.

Radiotherapy, chemotherapy and immunotherapy have been used with limited results for primary esophageal melanoma (10). None has been shown to improve prognosis. Intraluminal radiotherapy is now showing promising results. A case was recently reported of a patient treated with heavy ion radiation who achieved a complete response. However, lung and liver metastases were identified at month 5 of follow-up, requiring chemotherapy (11).

Prognosis is usually fatal with a 5-year survival rate of 4.2 to 37% according to the various series reported. Survival improves with early diagnosis (12).

The pathological diagnosis of primary malignant melanoma of the esophagus relies on the identification of an in-situ component and/or radial growth in the proximity of the invading melanoma, according to the criteria established by Allen and Spitz in 1952, later implemented for esophageal melanoma by Raven and Dawson (13).

Some authors have described the observed mixed squamous and fusiform growth pattern for primary esophageal melanoma in contrast to metastatic melanoma (14). This criterion may seemingly be useful for the differential diagnosis of primary melanoma. However, given the sparse number of reported cases and the need for thorough lesion sampling in order to identify such mixed pattern, we believe this finding cannot be considered as a valid criterion for the histological diagnosis of primary esophageal melanoma.

Immunohistochemical techniques are useful for the differential diagnosis between melanoma and carcinoma, with antigen HMB-45, protein S-100, and Melan-A being particularly relevant in association with negative cytokeratins and CEA. However, no immunohistochemical marker is available to help differentiate primary from metastatic melanoma. This renders the exclusion of prior or concomitant skin lesions a key factor for initial diagnosis.

Regarding tumor staging, there is no consensus on the system to be used. In our case we followed the 2010 TNM, seventh edition, and categorized the condition as T2N0M0. Presently some authors only classify these tumors as T3-T4. According to this, our patient would be categorized as T3 (15).

To conclude, we may assert that esophageal melanoma is a rare tumor with a poor outcome. Early diagnosis is a key for prognosis, and differential diagnosis from secondary melanoma is required. Surgery is the treatment providing the best outcome as of today.

REFERENCES


